Latest News

Commodities led widespread rallies in March for the major asset classes based on a set of ETFs.

Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles.

Ford saw a 5% rise in U.S. retail sales in Q1, driven by F-Series truck sales, which jumped 24%. The automaker also posted a 26% surge in electrified vehicle sales, with hybrid sales up 33% and the Mustang Mach-E leading the charge.

Trump's tariff plan, dubbed Liberation Day, could impose 20% tariffs on $3 trillion of imports. Goldman Sachs raises forecast to 18% by 2025.

For many investors, dividend stocks are a great way to generate passive income while maintaining the possibility of capital growth.

Full-year revenue shrank 13% year-over-year to $15.24 million compared to $17.56 million in 2023. Net loss widened to $48.32 million during the year compared to $17.28 million in 2023.

Rezolve AI (NASDAQ: RZLV) expected to see rapid revenue growth, analyst initiates coverage with Buy rating and $4 price target, citing potential in ecommerce market.

After opening the day on a flat note, Indian benchmark indices failed to rally and ended the first trading session of FY 2025-26 in negative territory.

Centuri Holdings secures over $360 million in new project awards, expanding its presence in the U.S. and Canada and focusing on utility, energy, and data center clients.

Intel Corp. just got a new chief executive, but it's going to take more than a fresh face to turn this ship around.

Truist described the keynote as "the most constructive message we've heard from Intel in ... for as long as we've covered the company."

Hype is contagious, and fear of missing out (FOMO) is powerful. But smart investing isn't about chasing trends—it's about understanding value.

Apple could have good news with foreign-branded phone shipments up year-over-year in China for the month of February.

The First Watch Restaurant Group's same store sales are expected to improve in 2025 due to marketing strategy changes and positive market trends.

GRI Bio reported interim Phase 2a results for GRI-0621 in IPF, showing safety and no significant cholesterol changes.